More than 3 character to search
GI Dynamics ,
Study Demonstrates People Living with Type 2 Diabetes and Obesity Can Be Successfully Treated with GI Dynamics’ EndoBarrier™ Gastrointestinal Liner for 12 Months
LEXINGTON, Mass. - (Business Wire) GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced initial, positive results from a clinical trial evaluating 12 months of treatment with the EndoBarrier™ Gastrointestinal Liner. The first group of patients from this trial have successfully completed 12 months, or 52 weeks, of treatment with the EndoBarrier Gastrointestinal Liner, an important milestone in the clinical development of this non-surgical therapeutic. The clinical trial was led by Eduardo G. Moura, M.D., Ph.D., director of endoscopy, digestive surgery department, Hospital das Clinicas, University of Sao Paulo, Brazil.